Skip to main content

10x Genomics, Inc. (TXG) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Health Information Services

Sell if holding. Engine safety override at $21.45: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 19%; Below-average business quality.

10x Genomics develops single-cell (Chromium) and spatial biology (Visium, Xenium) research instruments, consumables, and software for analyzing biological systems at cellular resolution, sold to academic, government, and biopharmaceutical researchers globally. Revenue was... Read more

$21.45+2.3% A.UpsideScore 4.9/10#12 of 13 Health Information Services
QualityF-score5 / 9FCF yield4.57%
Stop $19.95Target $21.95(analyst − 13%)A.R:R 0.2:1
Analyst target$25.23+17.6%13 analysts
$21.95our TP
$21.45price
$25.23mean
$20
$32

Sell if holding. Engine safety override at $21.45: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 19%; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 4.9/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Val6.2Qual3.7Grw6.0Mom5.2Sent6.8Ins3.9Peer1.8Tech6.2Risk2.44.9OVERALL

Recent Developments — 10x Genomics, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Chromium solutions
Target reached (2.3% upside)
Quality below floor (3.7 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)107.3
Mkt Cap$2.7B
EV/EBITDA-73.8
Profit Mgn-3.5%
ROE-3.0%
Rev Growth-2.6%
Beta2.05
DividendNone
Rating analysts22

Quality Signals

Piotroski F5/9

Options Flow

P/C0.88neutral
IV78%elevated
Max Pain$13-41.7% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductChromium solutions
    10-K Item 1A: 'Our dependency on revenue generated from the sale of our Chromium solutions'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.0
Quality Rank
2.4
Value Rank
4.6

Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Debt Equity
0.0
Implied Vol
0.3
Short Interest
1.6
Max Pain Risk
3.0
Beta
3.2
Days To Cover
3.8
Put Call
7.5
High short interest justified: 19%High IV: 78%Above max pain $12Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Unprofitable operations — net margin -3.5%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Rule Of 40
3.0
Moat
4.0
Piotroski F
5.6
Current Ratio
7.1
Fcf Quality
7.4
Gross Margin
9.9
FCF-positive despite GAAP loss (FCF margin 19%, FCF yield 4.6%)No competitive moatRule of 40: 17 (fail)
GatesA.R:R 0.2 < 1.5@spotMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.2>=4.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
50 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.53Resistance $25.18

Price Targets

$20
$22
A.Upside+2.3%
A.R:R0.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (2.3% upside)
! Quality below floor (3.7 < 4.0)
! Reward/Risk 0.2:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TXG stock a buy right now?

Sell if holding. Engine safety override at $21.45: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 19%; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $19.95. Score 4.9/10, moderate confidence.

What is the TXG stock price target?

Take-profit target: $21.95 (+2.3% upside). Prior stop was $19.95. Stop-loss: $19.95.

What are the risks of investing in TXG?

Concentration risk — Product: Chromium solutions; Target reached (2.3% upside); Quality below floor (3.7 < 4.0).

Is TXG overvalued or undervalued?

10x Genomics, Inc. trades at a P/E of N/A (forward 107.3). TrendMatrix value score: 6.2/10. Verdict: Sell.

What do analysts say about TXG?

22 analysts cover TXG with a consensus score of 3.6/5. Average price target: $25.

What does 10x Genomics, Inc. do?10x Genomics develops single-cell (Chromium) and spatial biology (Visium, Xenium) research instruments, consumables,...

10x Genomics develops single-cell (Chromium) and spatial biology (Visium, Xenium) research instruments, consumables, and software for analyzing biological systems at cellular resolution, sold to academic, government, and biopharmaceutical researchers globally. Revenue was $642.8M in 2025 with 8,046 cumulative instruments sold; no single customer exceeded 10% of business.

Related stocks: WAY (Waystar Holding Corp.) · VEEV (Veeva Systems Inc.) · HQY (HealthEquity, Inc.) · HNGE (Hinge Health, Inc.) · PRVA (Privia Health Group, Inc.)